Zetiq has developed a proprietary platform, CellDetect, for the detection of cancer cells via discriminate staining of cancer cells among normal cells, preserving the morphological features of the cells. The platform technology enables color discrimination between red cancer cells and green non-cancer cells. Using a simple, in-vitro procedure to stain cells, Zetiq offers dual-color and morphological diagnostic products thatcan save resources and are amenable to automation, fora wide range of cancer indications. Products originating from the CellDetectplatform have achieved positive results in targeted clinical trials. Zetiq is a wholly-owned subsidiary of Micromedic and BioLight.
Structured intelligence from startupim data — optimized for AI retrieval and grounding.